631 related articles for article (PubMed ID: 12477054)
1. Potent and specific inhibition of the breast cancer resistance protein multidrug transporter in vitro and in mouse intestine by a novel analogue of fumitremorgin C.
Allen JD; van Loevezijn A; Lakhai JM; van der Valk M; van Tellingen O; Reid G; Schellens JH; Koomen GJ; Schinkel AH
Mol Cancer Ther; 2002 Apr; 1(6):417-25. PubMed ID: 12477054
[TBL] [Abstract][Full Text] [Related]
2. Differential inhibition of murine Bcrp1/Abcg2 and human BCRP/ABCG2 by the mycotoxin fumitremorgin C.
González-Lobato L; Real R; Prieto JG; Alvarez AI; Merino G
Eur J Pharmacol; 2010 Oct; 644(1-3):41-8. PubMed ID: 20655304
[TBL] [Abstract][Full Text] [Related]
3. Overexpression of the ATP-binding cassette half-transporter, ABCG2 (Mxr/BCrp/ABCP1), in flavopiridol-resistant human breast cancer cells.
Robey RW; Medina-Pérez WY; Nishiyama K; Lahusen T; Miyake K; Litman T; Senderowicz AM; Ross DD; Bates SE
Clin Cancer Res; 2001 Jan; 7(1):145-52. PubMed ID: 11205902
[TBL] [Abstract][Full Text] [Related]
4. Role of breast cancer resistance protein in the bioavailability and fetal penetration of topotecan.
Jonker JW; Smit JW; Brinkhuis RF; Maliepaard M; Beijnen JH; Schellens JH; Schinkel AH
J Natl Cancer Inst; 2000 Oct; 92(20):1651-6. PubMed ID: 11036110
[TBL] [Abstract][Full Text] [Related]
5. Flavonoids chrysin and benzoflavone, potent breast cancer resistance protein inhibitors, have no significant effect on topotecan pharmacokinetics in rats or mdr1a/1b (-/-) mice.
Zhang S; Wang X; Sagawa K; Morris ME
Drug Metab Dispos; 2005 Mar; 33(3):341-8. PubMed ID: 15608138
[TBL] [Abstract][Full Text] [Related]
6. Mouse breast cancer resistance protein (Bcrp1/Abcg2) mediates etoposide resistance and transport, but etoposide oral availability is limited primarily by P-glycoprotein.
Allen JD; Van Dort SC; Buitelaar M; van Tellingen O; Schinkel AH
Cancer Res; 2003 Mar; 63(6):1339-44. PubMed ID: 12649196
[TBL] [Abstract][Full Text] [Related]
7. Reversal of breast cancer resistance protein (BCRP/ABCG2)-mediated drug resistance by novobiocin, a coumermycin antibiotic.
Shiozawa K; Oka M; Soda H; Yoshikawa M; Ikegami Y; Tsurutani J; Nakatomi K; Nakamura Y; Doi S; Kitazaki T; Mizuta Y; Murase K; Yoshida H; Ross DD; Kohno S
Int J Cancer; 2004 Jan; 108(1):146-51. PubMed ID: 14618629
[TBL] [Abstract][Full Text] [Related]
8. Gefitinib ("Iressa", ZD1839), an epidermal growth factor receptor tyrosine kinase inhibitor, reverses breast cancer resistance protein/ABCG2-mediated drug resistance.
Nakamura Y; Oka M; Soda H; Shiozawa K; Yoshikawa M; Itoh A; Ikegami Y; Tsurutani J; Nakatomi K; Kitazaki T; Doi S; Yoshida H; Kohno S
Cancer Res; 2005 Feb; 65(4):1541-6. PubMed ID: 15735043
[TBL] [Abstract][Full Text] [Related]
9. Fumitremorgin C reverses multidrug resistance in cells transfected with the breast cancer resistance protein.
Rabindran SK; Ross DD; Doyle LA; Yang W; Greenberger LM
Cancer Res; 2000 Jan; 60(1):47-50. PubMed ID: 10646850
[TBL] [Abstract][Full Text] [Related]
10. Modulation of breast cancer resistance protein (BCRP/ABCG2) gene expression using RNA interference.
Ee PL; He X; Ross DD; Beck WT
Mol Cancer Ther; 2004 Dec; 3(12):1577-83. PubMed ID: 15634651
[TBL] [Abstract][Full Text] [Related]
11. Effects of dihydropyridines and pyridines on multidrug resistance mediated by breast cancer resistance protein: in vitro and in vivo studies.
Zhou XF; Yang X; Wang Q; Coburn RA; Morris ME
Drug Metab Dispos; 2005 Aug; 33(8):1220-8. PubMed ID: 15908473
[TBL] [Abstract][Full Text] [Related]
12. The role of breast cancer resistance protein in acute lymphoblastic leukemia.
Plasschaert SL; van der Kolk DM; de Bont ES; Kamps WA; Morisaki K; Bates SE; Scheffer GL; Scheper RJ; Vellenga E; de Vries EG
Clin Cancer Res; 2003 Nov; 9(14):5171-7. PubMed ID: 14613996
[TBL] [Abstract][Full Text] [Related]
13. [Drug-resistant proteins in breast cancer: recent progress in multidrug resistance].
Wu DL; Huang F; Lu HZ
Ai Zheng; 2003 Apr; 22(4):441-4. PubMed ID: 12704006
[TBL] [Abstract][Full Text] [Related]
14. Flavonoids are inhibitors of breast cancer resistance protein (ABCG2)-mediated transport.
Zhang S; Yang X; Morris ME
Mol Pharmacol; 2004 May; 65(5):1208-16. PubMed ID: 15102949
[TBL] [Abstract][Full Text] [Related]
15. Molecular expression and functional evidence of a drug efflux pump (BCRP) in human corneal epithelial cells.
Karla PK; Earla R; Boddu SH; Johnston TP; Pal D; Mitra A
Curr Eye Res; 2009 Jan; 34(1):1-9. PubMed ID: 19172464
[TBL] [Abstract][Full Text] [Related]
16. Impact of BCRP/MXR, MRP1 and MDR1/P-Glycoprotein on thermoresistant variants of atypical and classical multidrug resistant cancer cells.
Stein U; Lage H; Jordan A; Walther W; Bates SE; Litman T; Hohenberger P; Dietel M
Int J Cancer; 2002 Feb; 97(6):751-60. PubMed ID: 11857350
[TBL] [Abstract][Full Text] [Related]
17. Sensitization of ABCG2-overexpressing cells to conventional chemotherapeutic agent by sunitinib was associated with inhibiting the function of ABCG2.
Dai CL; Liang YJ; Wang YS; Tiwari AK; Yan YY; Wang F; Chen ZS; Tong XZ; Fu LW
Cancer Lett; 2009 Jun; 279(1):74-83. PubMed ID: 19232821
[TBL] [Abstract][Full Text] [Related]
18. The "specific" P-glycoprotein inhibitor Tariquidar is also a substrate and an inhibitor for breast cancer resistance protein (BCRP/ABCG2).
Kannan P; Telu S; Shukla S; Ambudkar SV; Pike VW; Halldin C; Gottesman MM; Innis RB; Hall MD
ACS Chem Neurosci; 2011 Feb; 2(2):82-9. PubMed ID: 22778859
[TBL] [Abstract][Full Text] [Related]
19. Multidrug resistance mediated by the breast cancer resistance protein BCRP (ABCG2).
Doyle L; Ross DD
Oncogene; 2003 Oct; 22(47):7340-58. PubMed ID: 14576842
[TBL] [Abstract][Full Text] [Related]
20. Characterization of a Potent, Selective, and Safe Inhibitor, Ac15(Az8)
Chong TC; Wong ILK; Cui J; Law MC; Zhu X; Hu X; Kan JWY; Yan CSW; Chan TH; Chow LMC
Int J Mol Sci; 2022 Oct; 23(21):. PubMed ID: 36362047
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]